Trillium Therapeutics Overview

  • Founded
  • 2004
Founded
  • Status
  • Public
  • Employees
  • 33
Employees
  • Stock Symbol
  • TRIL
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $9.83
  • (As of Tuesday Closing)

Trillium Therapeutics General Information

Description

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
TSE
Primary Office
  • 2488 Dunwin Drive
  • Mississauga, Ontario L5L 1J9
  • Canada
+1 (416) 000-0000

Trillium Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Trillium Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.83 $10.09 $5.80 - $20.89 $1.04B 103M 162K $0.17

Trillium Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 824,017 1,306,049 26,770 21,886
Revenue 148 148 124 0
EBITDA (1,193) (60,653) (37,851) (31,229)
Net Income (139) (59,346) (38,082) (32,866)
Total Assets 288,288 300,822 26,393 40,780
Total Debt 794 831 1,035 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Trillium Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Trillium Therapeutics‘s full profile, request access.

Request a free trial

Trillium Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Jan Skvarka Ph.D Chief Executive Officer & Board Member
James Parsons Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Bob Uger Ph.D Chief Scientific Officer
Scott Duncan Director, Intellectual Property
Penka Petrova Executive
You’re viewing 5 of 11 executive team members. Get the full list »

Trillium Therapeutics Board Members (19)

Name Representing Role Since
0000 00000000 Self Board Member 000 0000
00000 000000-000000 00.0 Self Board Member 000 0000
000 0000000 00.0 Trillium Therapeutics Chief Executive Officer & Board Member 000 0000
0000 000000 Self Board Member 000 0000
0000000 0000000 00.0 Self Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Trillium Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Trillium Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Trillium Therapeutics‘s full profile, request access.

Request a free trial

Trillium Therapeutics Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000000 27-Jan-2016 000000000000000000 000.00 Drug Discovery 000 0000 00.0
00000000 000000000 09-Apr-2013 000000000000000000 00.000 Biotechnology 00000 00000
Stem Cell Therapeutics 12-Feb-2013 Merger/Acquisition Biotechnology
To view Trillium Therapeutics’s complete acquisitions history, request access »